Quick Answer
Tenaya Therapeutics, Inc. reported Total Assets of $146.92 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed an increase of +22.5% in Total Assets from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $156.90 million | Q3 2021: $331.79 million | Q1 2022: $281.50 million | Q2 2022: $255.93 million | Q3 2022: $226.31 million | Q1 2023: $245.34 million | Q2 2023: $220.75 million | Q3 2023: $193.40 million | Q1 2024: $184.90 million | Q2 2024: $163.19 million | Q3 2024: $140.58 million | Q1 2025: $143.95 million | Q2 2025: $122.15 million | Q3 2025: $104.98 million.
- Over the full 6 years of available data (2020 to 2025), Tenaya Therapeutics, Inc.'s Total Assets has declined by 0.8%.
- Historical annual values: Fiscal year 2025: $146.92 million | Fiscal year 2024: $119.94 million | Fiscal year 2023: $170.52 million | Fiscal year 2022: $278.95 million | Fiscal year 2021: $314.19 million | Fiscal year 2020: $148.16 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: